Clinical Trial Update: A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Bitopertin (RO4917838) in patients with persistent, predominant negative symptoms of schizophrenia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Bitopertin (bitopertin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED